Page 21 - காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால Today - Breaking & Trending Today

Pfizer Inc.: U.S. FDA Accepts for Priority Review Pfizer's Application for TicoVac (Tick-borne Encephalitis Vaccine)


Pfizer Inc.: U.S. FDA Accepts for Priority Review Pfizer s Application for TicoVac (Tick-borne Encephalitis Vaccine)
4 transmitted to humans through the bite of an infected tick,
5 and less frequently by ingestion of unpasteurized milk or milk products from infected animals.
4 It may initially be mistaken for summer flu,
18,19 but can be a serious condition with possible long-term consequences.
4,19 More than 1 in 3 people can have long-term effects that last months or years
including cognitive changes, muscle weakness or permanent paralysis,
4,19 and in rare cases (0.5-2%; up to 20% in Russia), people may die.
20,21 TBE can affect people of all ages who come into contact with ticks whenever they do outdoor activities in countries where ticks infected with TBE are prevalent. ....

Leningradskaya Oblast , United States , Elsevier Saunders , Nanette Cocero , Bryan Dunn , Steve Danehy , Health Pro , Drug Administration , Exchange Commission , Us Food Drug Administration , Pfizer Inc , Global Health , European Centre For Disease Prevention , Priority Review , Biologics License Application , Prescription Drug User Fee Act , European Centre , Disease Prevention , Global President , Far Eastern , Western Europe , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future ,

Zoetis Receives European Commission Marketing Authorization for Solensia® (frunevetmab), a New Therapy for Feline Osteoarthritis Pain


Share:
Solensia is the first injectable monoclonal antibody (mAb) licensed for alleviation of pain associated with osteoarthritis (OA) in cats
Solensia works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA pain
European Commission Marketing Authorization for a similar product in dogs, Librela
®,
was received in November 2020
Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia
® (frunevetmab), a new feline osteoarthritis treatment to alleviate pain. Osteoarthritis in cats is a very prevalent condition
1, existing in 40% of cats, and may generate pain and limit a cat s comfort and quality of life if not treated. ....

Catherine Knupp , Margarete Gruen , Mike Mcfarland , Rob Kelly , Clin Pharmacokinet , Zoetis Veterinarian Market Research , European Commission Marketing Authorization , European Commission , Zoetis Inc , International Operations At Zoetis , Nerve Growth Factor , Commission Marketing Authorization , Executive Vice President , Assistant Professor , Behavioral Medicine , North Carolina State University , Chief Medical Officer , International Operations , Looking Statements , Annual Report , Factors That May Affect Future , Quarterly Reports , Current Reports , Veterinarian Market Research , Project November , கேத்தரின் க்னுபப் ,

Zoetis Inc.: Zoetis Receives European Commission Marketing Authorization for Solensia (frunevetmab), a New Therapy for Feline Osteoarthritis Pain


Zoetis Inc.: Zoetis Receives European Commission Marketing Authorization for Solensia (frunevetmab), a New Therapy for Feline Osteoarthritis Pain
Solensia works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA pain
European Commission Marketing Authorization for a similar product in dogs, Librela
,
was received in November 2020
Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia
(frunevetmab), a new feline osteoarthritis treatment to alleviate pain. Osteoarthritis in cats is a very prevalent condition
1, existing in 40% of cats, and may generate pain and limit a cat s comfort and quality of life if not treated. ....

Catherine Knupp , Margarete Gruen , Mike Mcfarland , Rob Kelly , Bill Price , Clin Pharmacokinet , Zoetis Veterinarian Market Research , European Commission Marketing Authorization , European Commission , Zoetis Inc , International Operations At Zoetis , Nerve Growth Factor , Commission Marketing Authorization , Executive Vice President , Assistant Professor , Behavioral Medicine , North Carolina State University , Chief Medical Officer , International Operations , Looking Statements , Annual Report , Factors That May Affect Future , Quarterly Reports , Current Reports , Veterinarian Market Research , Project November ,